Investor Relations

Corporate Profile

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary RNA Armory® platform, Cartesian’s internally manufactured portfolio is purposefully designed to be administered conveniently in an outpatient setting without preconditioning chemotherapy. The Company’s portfolio includes its Phase 2 lead asset, Descartes-08, an autologous anti-BCMA mRNA CAR-T. In a Phase 2 study in patients with myasthenia gravis, Descartes-08 was observed to be safe and well-tolerated, and to induce deep and durable responses.

Data Provided by Refinitiv. Minimum 15 minutes delayed.